Literature DB >> 30927035

Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies.

A Salari-Moghaddam1,2, O Sadeghi1, A H Keshteli3,4, B Larijani5, A Esmaillzadeh6,7,8.   

Abstract

INTRODUCTION: No study is available summarizing earlier publications on the association between metformin use and risk of fracture. This systematic review and meta-analysis were conducted to summarize earlier findings on the association between metformin use and risk of fracture.
METHODS: We conducted a systematic search on all published articles up to October 2018 using online databases including PubMed/Medline, ISI Web of Science, and Scopus. Observational studies that considered metformin use as the exposure variable and bone fracture as the main outcome variable or as one of the outcome variables and participants included were 18 years and older were included in the systematic review. Publications in which hazard ratios (HRs), rate or risk ratios (RRs), or odds ratios (ORs) were reported as effect size were included in the meta-analysis.
RESULTS: Totally, three cohort studies, one cross-sectional study, one nested case-control study, and one case-control study were included in this systematic review and meta-analysis. When seven effect sizes from six studies were combined, a significant inverse association between metformin use and risk of fracture was observed (RR 0.82; 95% CI 0.72, 0.93). No significant between-study heterogeneity was found (I2 = 22.4%, Pheterogeneity = 0.25). In addition, no evidence of publication bias was seen using Egger's test (P = 0.99).
CONCLUSION: We found that metformin use was inversely associated with the risk of fracture.

Entities:  

Keywords:  Fracture; Meta-analysis; Metformin; Systematic review

Mesh:

Substances:

Year:  2019        PMID: 30927035     DOI: 10.1007/s00198-019-04948-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  28 in total

1.  Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus.

Authors:  Ippei Kanazawa; Toru Yamaguchi; Masahiro Yamamoto; Toshitsugu Sugimoto
Journal:  J Bone Miner Metab       Date:  2010-02-23       Impact factor: 2.626

2.  Metformin for Rapidly Maturing Girls with Central Adiposity: Less Liver Fat and Slower Bone Maturation.

Authors:  Francis de Zegher; Cristina García Beltrán; Abel López-Bermejo; Lourdes Ibáñez
Journal:  Horm Res Paediatr       Date:  2017-11-07       Impact factor: 2.852

3.  Metformin Enhances Osteogenesis and Suppresses Adipogenesis of Human Chorionic Villous Mesenchymal Stem Cells.

Authors:  Qiaoli Gu; Yanzheng Gu; Huilin Yang; Qin Shi
Journal:  Tohoku J Exp Med       Date:  2017-01       Impact factor: 1.848

4.  Vertebral Fracture Risk in Diabetic Elderly Men: The MrOS Study.

Authors:  Nicola Napoli; Ann V Schwartz; Anne L Schafer; Eric Vittinghoff; Peggy M Cawthon; Neeta Parimi; Eric Orwoll; Elsa S Strotmeyer; Andrew R Hoffman; Elizabeth Barrett-Connor; Dennis M Black
Journal:  J Bone Miner Res       Date:  2017-12-27       Impact factor: 6.741

Review 5.  Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture.

Authors:  Mohsen Janghorbani; Rob M Van Dam; Walter C Willett; Frank B Hu
Journal:  Am J Epidemiol       Date:  2007-06-16       Impact factor: 4.897

6.  Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study.

Authors:  Matteo Monami; Barbara Cresci; Angela Colombini; Laura Pala; Daniela Balzi; Francesca Gori; Veronica Chiasserini; Niccolò Marchionni; Carlo Maria Rotella; Edoardo Mannucci
Journal:  Diabetes Care       Date:  2007-11-16       Impact factor: 19.112

7.  A cohort study of thiazolidinediones and fractures in older adults with diabetes.

Authors:  Daniel H Solomon; Suzanne M Cadarette; Niteesh K Choudhry; Claire Canning; Raisa Levin; Til Stürmer
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

8.  Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

Authors:  Steven E Kahn; Bernard Zinman; John M Lachin; Steven M Haffner; William H Herman; Rury R Holman; Barbara G Kravitz; Dahong Yu; Mark A Heise; R Paul Aftring; Giancarlo Viberti
Journal:  Diabetes Care       Date:  2008-01-25       Impact factor: 19.112

9.  Evaluation of bone mineral density in type 2 diabetes mellitus patients before and after treatment.

Authors:  Mk Dutta; R Pakhetra; Mk Garg
Journal:  Med J Armed Forces India       Date:  2012-01-18

10.  Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.

Authors:  H M Colhoun; S J Livingstone; H C Looker; A D Morris; S H Wild; R S Lindsay; C Reed; P T Donnan; B Guthrie; G P Leese; J McKnight; D W M Pearson; E Pearson; J R Petrie; S Philip; N Sattar; F M Sullivan; P McKeigue
Journal:  Diabetologia       Date:  2012-09-04       Impact factor: 10.122

View more
  8 in total

1.  Unmasking Fracture Risk in Type 2 Diabetes: The Association of Longitudinal Glycemic Hemoglobin Level and Medications.

Authors:  Bowen Wang; Zehai Wang; Atharva A Poundarik; Mohammed J Zaki; Richard S Bockman; Benjamin S Glicksberg; Girish N Nadkarni; Deepak Vashishth
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

Review 2.  Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next?

Authors:  Moein Ala; Mahan Ala
Journal:  ACS Pharmacol Transl Sci       Date:  2021-11-01

3.  Risk of Fracture With Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis Combining 177 Randomized Controlled Trials With a Median Follow-Up of 26 weeks.

Authors:  Sanbao Chai; Fengqi Liu; Zhirong Yang; Shuqing Yu; Zuoxiang Liu; Qingqing Yang; Feng Sun
Journal:  Front Pharmacol       Date:  2022-07-01       Impact factor: 5.988

Review 4.  Targeting Sirt1, AMPK, Nrf2, CK2, and Soluble Guanylate Cyclase with Nutraceuticals: A Practical Strategy for Preserving Bone Mass.

Authors:  Mark F McCarty; Lidianys Lewis Lujan; Simon Iloki Assanga
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 5.  Mapping Knowledge Landscapes and Emerging Trends of the Links Between Bone Metabolism and Diabetes Mellitus: A Bibliometric Analysis From 2000 to 2021.

Authors:  Kunming Cheng; Qiang Guo; Weiguang Yang; Yulin Wang; Zaijie Sun; Haiyang Wu
Journal:  Front Public Health       Date:  2022-06-03

Review 6.  Diabetes and Bone Involvement in Primary Hyperparathyroidism: Literature Review and Our Personal Experience.

Authors:  Elena Castellano; Roberto Attanasio; Alberto Boriano; Valentina Borretta; Francesco Tassone; Giorgio Borretta
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-19       Impact factor: 5.555

Review 7.  The Interplay Between Bone and Glucose Metabolism.

Authors:  Cristiana Cipriani; Luciano Colangelo; Rachele Santori; Mario Renella; Monia Mastrantonio; Salvatore Minisola; Jessica Pepe
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-24       Impact factor: 5.555

8.  Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.

Authors:  Yu-Sheng Zhang; Yan-Dan Zheng; Yan Yuan; Shi-Chun Chen; Bao-Cheng Xie
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-14       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.